GP data quietly added to Palantir’s NHS data platform
Palantir’s NHS data platform has quietly added GP data in a pilot, expanding the software beyond its existing hospital use. The move broadens PLTR’s public-sector footprint but also deepens scrutiny around privacy, consent and the company’s controversial role in UK healthcare.
The Financial Times reported that GP data has been added to Palantir’s NHS data platform through a pilot. The report described the step as a significant expansion beyond the software’s current use in hospitals, but did not disclose the participating practices, the volume of records involved or the commercial terms.
Palantir’s NHS role has already drawn controversy because its software is used to connect and analyze healthcare information across services. Adding general-practice data extends the platform into a more sensitive and broader source of patient information, changing the scope of the deployment even though the report did not say that the pilot has become a nationwide rollout.
For Palantir, the direct mechanism is public-sector software adoption: a wider NHS deployment could create additional usage and reference value for its government business. For the NHS, the mechanism is operational access to data held outside hospitals, while for patients and privacy advocates the relevant issue is how access, governance and consent are handled.
The Financial Times did not report a contract value, revenue contribution, timetable for expansion or reaction from NHS officials, Palantir or opponents of the arrangement. It also did not establish whether the pilot will proceed to a broader deployment, leaving the commercial impact and political durability uncertain.
The next evidence should be the pilot’s participating organizations, governance terms and any decision on expansion. Palantir’s next reported results will also show whether government growth is translating into revenue, but the report does not provide a date for that release.
The NHS pilot is incrementally positive for PLTR’s government software footprint, but the lack of contract or revenue detail keeps the commercial read modest.
The strategic value is broader NHS penetration: GP data gives Palantir a larger potential healthcare deployment and a public-sector reference point, while the company’s $4.5B FY2025 revenue and 56.2% year-over-year growth show an established commercial base. The missing contract value, rollout timetable and governance terms prevent this pilot from supporting a dated directional call on the shares.
The pilot could stall or face political and privacy-related resistance before expanding beyond its current scope.
CoverageSource: Financial Times · Published here SUN, SEP 13 · 12:00 AM ET · the only report in this recordHow this is decided →
STOCK PHOTO · PHIL EVENDENEarlier context and later coverage are dated relative to this report. Automatically linked reports may cover a broader event.
No later reports linked yet.
Follow this story to find new evidence in your Following desk.
A move from hospital use into GP data could widen Palantir’s NHS footprint and create additional government-software demand on top of FY2025 revenue of $4.5B.
The Financial Times disclosed no contract value or rollout commitment, while controversy over patient-data access could limit the pilot’s commercial conversion.
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →